Anzeige
Mehr »
Samstag, 07.06.2025 - Börsentäglich über 12.000 News
Der nächste Perpetua? Warum NevGolds neueste Bohrergebnisse den Vergleich mit dem Milliardenwert PPTA nähren
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2N87T | ISIN: SE0007413455 | Ticker-Symbol: 78D
Frankfurt
06.06.25 | 08:01
0,114 Euro
-14,41 % -0,019
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
ALZINOVA AB Chart 1 Jahr
5-Tage-Chart
ALZINOVA AB 5-Tage-Chart

Aktuelle News zur ALZINOVA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
28.05.Alzinova AB: Bulletin from the Annual General Meeting of Alzinova AB (publ)72Alzinova AB (publ) (the "Company") held its Annual General Meeting ("AGM") in Gothenburg on 28 May 2025. The following resolutions were passed at the meeting. Adoption of the annual accounts and discharge...
► Artikel lesen
15.05.Alzinova AB: Alzinova publishes interim report January - March 202579The Board of Directors and the Chief Executive Officer of Alzinova AB hereby present the interim report for the period January - March 2025. The full report, which is attached in the press release,...
► Artikel lesen
24.04.Alzinova AB: Alzinova Advances ALZ-101 Development with Drug Substance Release, Paving the Way for Phase 2 Clinical Trial176Alzinova AB (publ) (ticker: ALZ) is pleased to announce the release of the drug substance for its upcoming Phase 2 clinical trial of the vaccine candidate ALZ-101 in early Alzheimer's disease. This...
► Artikel lesen
11.04.XFRA CAPITAL ADJUSTMENT INFORMATION - 11.04.2025274Das Instrument J1X BMG4660A1036 HIMALAYA SHIPPING LTD DL1 EQUITY wird cum Kapitalmassnahme gehandelt am 11.04.2025 und ex Kapitalmassnahme am 14.04.2025 The instrument J1X BMG4660A1036 HIMALAYA SHIPPING...
► Artikel lesen
02.04.Alzinova AB: The Board of Directors of Alzinova resolves on a rights issue of shares of approximately SEK 35.7 million113NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, JAPAN, NEW ZEALAND, SOUTH AFRICA, SOUTH KOREA, CANADA, THE UNITED...
► Artikel lesen
ALZINOVA Aktie jetzt für 0€ handeln
27.03.Alzinova AB: Final results confirm positive phase 1b results with ALZ-101 against Alzheimer's disease338Alzinova AB (publ) (ticker: ALZ) today announces that the final analysis of data from the Phase 1b clinical study with the vaccine candidate ALZ-101, which included patients with early Alzheimer's disease...
► Artikel lesen
07.03.Alzinova AB: Bulletin from the Extraordinary General Meeting of Alzinova AB (publ)154The following resolution were passed at the extraordinary general meeting (the "EGM") of Alzinova AB (publ) ("the Company") on 7 March 2025 in Gothenburg. Long-term incentive program (LTIP 2025:1 for...
► Artikel lesen
27.02.Alzinova AB: Alzinova publishes year-end report 2024191The Board of Directors and the Chief Executive Officer of Alzinova AB hereby present the year-end report for the period January - December, and the fourth quarter, 2024. The full report, which is attached...
► Artikel lesen
03.02.Alzinova AB: All study participants have completed the final visit in the Phase 1 study209Alzinova AB (publ) (ticker: ALZ) announces that another milestone in the development of the company's vaccine candidate ALZ-101 for Alzheimer's disease has been reached. All study participants have...
► Artikel lesen
28.01.Alzinova AB: Alzinova strategically realigns CMO position to enhance collaboration and drive next development phase323Alzinova AB (publ) (ticker: ALZ) hereby announces that the Company's CMO is stepping down from her role after mutual agreement. The basis is a strategic decision to appoint a CMO in place at the Company's...
► Artikel lesen
09.12.24Alzinova AB: Alzinova reports positive results from the phase 1b extension part of the ALZ-101 study in Alzheimer's disease277ALZ-101 continues to demonstrate a favorable safety and tolerability profile after at least 84 weeks of study inclusion.The immune response from vaccination with ALZ-101 is robust and long-lasting in...
► Artikel lesen
14.11.24Alzinova AB: Alzinova publishes interim report January - September 2024225The Board of Directors and the Chief Executive Officer of Alzinova AB hereby present the interim report for the period January - September, and the third quarter, 2024. The full interim report, which...
► Artikel lesen
22.08.24Alzinova AB: Alzinova publishes interim report January - June 2024185The Board of Directors and the Chief Executive Officer of Alzinova AB hereby present the interim report for the period April - June, and the first half year, 2024. The full interim report, which is...
► Artikel lesen
13 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1